An observational study in Type 1 Diabetes Mellitus, sponsored by Buckinghamshire Healthcare NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-08.
Sponsored by Buckinghamshire Healthcare NHS Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 50th largest by planned enrollment of the 54 observational ones that give a count, is one of 11 that started in 2011, is one of 54 observational ones, and was the 57th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:
Sanofi · Sites in United Kingdom, Belgium, France and 3 more countries
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 16 more countries
Ages 1–35
Imperial College London · Sites in United Kingdom
Ages 18+
SAb Biotherapeutics, Inc. · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 5–40
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 31 · Phase 3 53 · Phase 4 18
First in 1997; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 214 interventional studies, 133 across the 54 observational. Of the 206 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 268 have an industry lead sponsor. The 10 most frequent:
Buckinghamshire Healthcare NHS Trust is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Buckinghamshire Healthcare NHS Trust has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
14 of the studies in Diabetes Mellitus, Type 1 with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
| NCT07583238University of NottinghamDiathermy On Diabetes Glucose Monitoring Effectiveness | 2027-02 |
| NCT06815081University of OxfordCapillary OGTT Study | 2027-02-28 |
| NCT07251257University of SurreyThe Seafarers' Continuous Glucose Monitoring Systems Study | 2027-03-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with Type 1 Diabetes Mellitus (T1DM) like to take part in sport and exercise, but problems with metabolism and blood glucose control can make this difficult. Some people with T1DM administer their insulin via an insulin pump, also know as continuous subcutaneous insulin infusion (CSII) therapy, in which a background or basal level of insulin is constantly infused under the skin by a special pump, with bolus doses of insulin given to accompany food. Clinical experience suggests that this may be particularly useful for managing diabetes for exercise, but there is limited experimental evidence to support this. The aim of this research , which is divided into three parts, is to investigate the hypothesis that the physiological response to sub-maximal (moderate) exercise of a person with type 1 diabetes treated with CSII, can be made to approximate more closely to the physiological response of a healthy individual by a prior reduction of their basal insulin infusion rate. This first part of the research is designed to compare metabolic response to exercise between people without diabetes and people with T1DM running there insulin pump at the usual basal rate.
For the first part of the study, participants will be either people with type 1 diabetes treated with insulin pump therapy or volunteers without diabetes. The 2 groups will be matched as far as possible by age, body mass index and usual level of activity. Participants will attend an exercise laboratory on 2 occasions. On the first occasion, which can take place at any time of day, formal written consent will be obtained for participation in the study. Participants will then undergo measurement of maximal exercise capacity (VO2 MAX). On the second occasion they will attend 2 hours after a lunch containing 60 grams of carbohydrate (advice will be given on how this can be achieved). A cannula will be inserted on arrival and blood samples obtained. Arterialised samples will be obtained by using a heated hand technique. Once the cannula has been inserted participants with type 1 diabetes will be asked to reduce the basal insulin infusion rate on their insulin pump to 70% of normal until the end of the study visit. After 30 minutes a further set of blood samples will be obtained, and participants will then start to exercise for 1 hour at 50% VO2 MAX. A further set of blood samples will be obtained at the end of the hour of exercise. Participants will then rest for 30 minutes before a final set of blood samples is taken. At this point the cannula will be removed and the study visit ends. Participants with diabetes will be given the choice to return basal insulin infusion rate to normal at this point. A snack will be offered.
Blood glucose will be monitored every 10 minutes and also if a participant feels symptoms of hypoglycaemia. If hypoglycaemia occurs the protocol will be stopped and carbohydrate given until the blood glucose level returns to the normal range.
Participants with Type 1 Diabetes treated with insulin pump therapy who exercise for at least 1 hour each week and comparable participants without diabetes mellitus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants with Type 1 Diabetes Mellitus
For participants without Type 1 Diabetes Mellitus
Exclusion Criteria:
For participants with type 1 Diabetes Mellitus
People with any one of the following complications of diabetes:
For participants without Type 1 Diabetes Mellitus
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
Participants without diabetes or evidence of impaired glucose regulation
Glucose excursion
The primary outcome measure is change in blood glucose (glucose excursion) between the start and the end of exercise
Time frame: Glucose will be measured at the start and end of 1 hour of exercise at 50% VO2 MAX during the second study visit
Comparison between the two groups of levels of lactate
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Multiple correlation between blood glucose values and values of lactate, NEFA, betahydroxybutyrate, catecholamines, glucagon, insulin, C-peptide, human growth hormone and cortisol
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise, compared between the two groups, which will give information about fuel use during exercise.
Time frame: Respiratory quotient will be calculated using a breath by breath analyser using 2 minutes of data from the start at the end of exercise
Comparison between the two groups of levels of non-esterified fatty acids (NEFA)
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of beta-hydroxybutyrate
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of circulating catecholamines
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of glucagon
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of circulating insulin
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of human growth hormone
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
Comparison between the two groups of levels of cortisol
Time frame: Samples will be obtained on arrival, 30 minutes later (at the start of exercise), at the end of exercise (1 hour later) and at the end of the study visit (30 minutes later)
The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Buckinghamshire Healthcare NHS Trust